Financial Ratios Oxford Nanopore Technologies plc
Equities
ONT
GB00BP6S8Z30
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 135.60 GBX | +0.44% |
|
-7.05% | +5.84% |
| 02-03 | UK's FTSE 100 in the Red; Britain Pursues Stronger Ties with Switzerland, Japan | MT |
| 02-03 | UK, Japan Ink Life Sciences, Quantum, Connectivity Partnership Deals | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -20.48 | -18.31 | -7.39 | -13.16 | -12.53 | |||||
Return on Total Capital | -27.01 | -21.92 | -8.45 | -14.91 | -14.45 | |||||
Return On Equity % | -41.46 | -37.67 | -13.03 | -23.11 | -23.77 | |||||
Return on Common Equity | -41.46 | -37.67 | -13.03 | -23.11 | -23.77 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 41.17 | 54.76 | 62.34 | 53.33 | 57.53 | |||||
SG&A Margin | 62.7 | 121.02 | 79.28 | 91.33 | 85.45 | |||||
EBITDA Margin % | -55.27 | -113.42 | -41.52 | -88.66 | -75.67 | |||||
EBITA Margin % | -64.17 | -123.06 | -49.56 | -99.33 | -83.02 | |||||
EBIT Margin % | -64.17 | -123.1 | -49.59 | -99.38 | -83.16 | |||||
Income From Continuing Operations Margin % | -53.79 | -125.4 | -45.83 | -91.06 | -79.8 | |||||
Net Income Margin % | -53.79 | -125.4 | -45.83 | -91.06 | -79.8 | |||||
Net Avail. For Common Margin % | -53.79 | -125.4 | -45.83 | -91.06 | -79.8 | |||||
Normalized Net Income Margin | -40.16 | -77.05 | -31.42 | -55.28 | -48.18 | |||||
Levered Free Cash Flow Margin | -38.51 | -116.16 | -23.94 | -44.46 | -44.87 | |||||
Unlevered Free Cash Flow Margin | -38.1 | -115.74 | -23.43 | -43.65 | -43.66 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.51 | 0.24 | 0.24 | 0.21 | 0.24 | |||||
Fixed Assets Turnover | 2.36 | 2.32 | 3.17 | 2.33 | 2 | |||||
Receivables Turnover (Average Receivables) | 3.5 | 2.99 | 4.99 | 4.52 | 5.13 | |||||
Inventory Turnover (Average Inventory) | 2.41 | 1.23 | 0.99 | 0.84 | 0.77 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.81 | 7.15 | 6.22 | 5.01 | 4.66 | |||||
Quick Ratio | 2.17 | 5.22 | 5.24 | 3.73 | 3.66 | |||||
Operating Cash Flow to Current Liabilities | -0.88 | -0.51 | -0.48 | -1.54 | -0.99 | |||||
Days Sales Outstanding (Average Receivables) | 104.5 | 122.02 | 73.2 | 80.68 | 71.29 | |||||
Days Outstanding Inventory (Average Inventory) | 152.07 | 297.89 | 367.89 | 436.15 | 472.82 | |||||
Average Days Payable Outstanding | 95.21 | 106.9 | 80.01 | 94.72 | 136.54 | |||||
Cash Conversion Cycle (Average Days) | 161.37 | 313.01 | 361.07 | 422.11 | 407.56 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 12.71 | 3.52 | 4.92 | 6.47 | 7.84 | |||||
Total Debt / Total Capital | 11.28 | 3.4 | 4.69 | 6.08 | 7.27 | |||||
LT Debt/Equity | 11.61 | 3.15 | 2.75 | 5.8 | 6.93 | |||||
Long-Term Debt / Total Capital | 10.3 | 3.05 | 2.62 | 5.45 | 6.42 | |||||
Total Liabilities / Total Assets | 33.88 | 16.38 | 15.82 | 17.14 | 20.98 | |||||
EBIT / Interest Expense | -97.8 | -181.2 | -60.49 | -76.43 | -42.73 | |||||
EBITDA / Interest Expense | -81.07 | -164.03 | -47.9 | -65.91 | -37.24 | |||||
(EBITDA - Capex) / Interest Expense | -102.14 | -187.74 | -62.07 | -68.59 | -41.15 | |||||
Total Debt / EBITDA | -0.39 | -0.17 | -0.44 | -0.29 | -0.35 | |||||
Net Debt / EBITDA | 0.95 | 3.11 | 5.67 | 1.57 | 2.2 | |||||
Total Debt / (EBITDA - Capex) | -0.31 | -0.15 | -0.34 | -0.28 | -0.31 | |||||
Net Debt / (EBITDA - Capex) | 0.75 | 2.72 | 4.37 | 1.51 | 1.99 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 118.7 | 17.39 | 48.59 | -14.57 | 7.97 | |||||
Gross Profit, 1 Yr. Growth % | 82.99 | 56.14 | 69.15 | -26.92 | 16.48 | |||||
EBITDA, 1 Yr. Growth % | -9.8 | 140.87 | -45.6 | 82.43 | -7.85 | |||||
EBITA, 1 Yr. Growth % | -9.68 | 125.13 | -40.16 | 71.23 | -9.77 | |||||
EBIT, 1 Yr. Growth % | -9.68 | 125.2 | -40.15 | 71.21 | -9.65 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -15.19 | 173.68 | -45.69 | 69.74 | -5.38 | |||||
Net Income, 1 Yr. Growth % | -15.19 | 173.68 | -45.69 | 69.74 | -5.38 | |||||
Normalized Net Income, 1 Yr. Growth % | -9.11 | 125.25 | -39.41 | 50.31 | -5.89 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -19.71 | 163.73 | -51.75 | 67.66 | -12.11 | |||||
Accounts Receivable, 1 Yr. Growth % | 260.29 | -24.41 | 7.04 | -17.85 | 10.96 | |||||
Inventory, 1 Yr. Growth % | 77.83 | 77.03 | 39.05 | 15.79 | -2.06 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 22.71 | 16.39 | 2.07 | 30.4 | 22.78 | |||||
Total Assets, 1 Yr. Growth % | 70.7 | 199.37 | -2.14 | -5.68 | -4.51 | |||||
Tangible Book Value, 1 Yr. Growth % | 69.35 | 279.31 | -2.56 | -7.43 | -11.2 | |||||
Common Equity, 1 Yr. Growth % | 69.76 | 278.62 | -1.48 | -7.17 | -8.93 | |||||
Cash From Operations, 1 Yr. Growth % | 31.08 | -15.64 | -7.17 | 115.12 | -19.97 | |||||
Capital Expenditures, 1 Yr. Growth % | -14.76 | 36.85 | 7.13 | -31.58 | 136.08 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -49.01 | 254.08 | 93.01 | 38.86 | 8.96 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -49.33 | 256.58 | 93.33 | 38.93 | 7.98 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 87.11 | 60.23 | 32.07 | 12.67 | -3.96 | |||||
Gross Profit, 2 Yr. CAGR % | 71.09 | 69.03 | 62.51 | 11.18 | -7.74 | |||||
EBITDA, 2 Yr. CAGR % | 5.45 | 47.4 | 14.47 | -0.38 | 29.66 | |||||
EBITA, 2 Yr. CAGR % | 7.91 | 42.6 | 16.07 | 1.22 | 24.3 | |||||
EBIT, 2 Yr. CAGR % | 7.91 | 42.62 | 16.1 | 1.23 | 24.37 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 7.38 | 52.35 | 21.91 | -3.99 | 26.73 | |||||
Net Income, 2 Yr. CAGR % | 7.38 | 52.35 | 21.91 | -3.99 | 26.73 | |||||
Normalized Net Income, 2 Yr. CAGR % | 8.6 | 43.08 | 16.82 | -4.57 | 18.93 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 4.55 | 35.83 | 12.81 | -10.05 | 21.39 | |||||
Accounts Receivable, 2 Yr. CAGR % | 109.69 | 65.03 | -10.05 | -6.23 | -4.53 | |||||
Inventory, 2 Yr. CAGR % | 38.39 | 77.43 | 56.89 | 26.89 | 6.49 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 41.79 | 19.51 | 8.99 | 15.37 | 26.53 | |||||
Total Assets, 2 Yr. CAGR % | 26.7 | 126.06 | 71.17 | -3.93 | -5.1 | |||||
Tangible Book Value, 2 Yr. CAGR % | 13.93 | 153.45 | 89.13 | -2.93 | -11.53 | |||||
Common Equity, 2 Yr. CAGR % | 14.07 | 153.52 | 93.14 | -4.37 | -8.05 | |||||
Cash From Operations, 2 Yr. CAGR % | 6.67 | 5.15 | -12.02 | 60.64 | 31.21 | |||||
Capital Expenditures, 2 Yr. CAGR % | 18.62 | 8 | 21.08 | -47.63 | 27.09 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -14.32 | 34.37 | 4.13 | 75.01 | 23.01 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -14.59 | 34.42 | 3.56 | 75.43 | 22.48 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 102.13 | 60.18 | 56.25 | 14.22 | 11.08 | |||||
Gross Profit, 3 Yr. CAGR % | 91.02 | 65.95 | 69.07 | 24.51 | 12.92 | |||||
EBITDA, 3 Yr. CAGR % | -0.61 | 38.87 | 5.73 | 33.71 | -2.94 | |||||
EBITA, 3 Yr. CAGR % | 3.5 | 37.88 | 6.76 | 32.13 | -2.58 | |||||
EBIT, 3 Yr. CAGR % | 3.5 | 37.9 | 6.78 | 32.15 | -2.54 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 2.7 | 46.67 | 8.02 | 36.13 | -4.46 | |||||
Net Income, 3 Yr. CAGR % | 2.7 | 46.67 | 8.02 | 36.13 | -4.46 | |||||
Normalized Net Income, 3 Yr. CAGR % | 3.56 | 38.5 | 7.45 | 27.06 | -5.01 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -1.56 | 35.93 | -3.8 | 28.74 | -10.74 | |||||
Accounts Receivable, 3 Yr. CAGR % | 124.55 | 49.24 | 42.85 | -12.73 | -0.82 | |||||
Inventory, 3 Yr. CAGR % | 76.78 | 50.23 | 63.58 | 41.79 | 16.39 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 35.52 | 32.76 | 13.39 | 15.71 | 17.79 | |||||
Total Assets, 3 Yr. CAGR % | 33.08 | 68.75 | 71.01 | 40.33 | -4.12 | |||||
Tangible Book Value, 3 Yr. CAGR % | 25.61 | 70.12 | 82.3 | 51.24 | -7.3 | |||||
Common Equity, 3 Yr. CAGR % | 25.71 | 70.16 | 85.01 | 51.29 | -5.91 | |||||
Cash From Operations, 3 Yr. CAGR % | -1.29 | -1.36 | 0.48 | 29.1 | 27.35 | |||||
Capital Expenditures, 3 Yr. CAGR % | -7.25 | 24.41 | 7.71 | -27.87 | -13.49 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -4.68 | 37.49 | -17.93 | 19.83 | 49.44 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -5.01 | 37.53 | -18.4 | 19.52 | 49.23 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 173.35 | 96.79 | 70.49 | 39.15 | 28.61 | |||||
Gross Profit, 5 Yr. CAGR % | 203.52 | 157.62 | 79.06 | 41.39 | 32.69 | |||||
EBITDA, 5 Yr. CAGR % | 7.81 | 18.97 | 5.17 | 21.59 | 14.72 | |||||
EBITA, 5 Yr. CAGR % | 10.57 | 20.42 | 8.36 | 21.85 | 13.46 | |||||
EBIT, 5 Yr. CAGR % | 10.57 | 20.43 | 8.37 | 21.86 | 13.5 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 9.72 | 23.18 | 9.99 | 23.81 | 15.15 | |||||
Net Income, 5 Yr. CAGR % | 9.72 | 23.18 | 9.99 | 23.81 | 15.15 | |||||
Normalized Net Income, 5 Yr. CAGR % | 10.87 | 20.56 | 8.67 | 19.33 | 11.9 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 4.92 | 15.88 | 1.13 | 15.23 | 5.58 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | 94.28 | 55.74 | 23.92 | 21.59 | |||||
Inventory, 5 Yr. CAGR % | 338.4 | 184.23 | 68.54 | 40.42 | 37.77 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 94.89 | 77.93 | 24.21 | 25.51 | 18.47 | |||||
Total Assets, 5 Yr. CAGR % | 20.92 | 39.57 | 47.18 | 34.71 | 35.12 | |||||
Tangible Book Value, 5 Yr. CAGR % | 13.22 | 37.29 | 47.96 | 35.04 | 37.71 | |||||
Common Equity, 5 Yr. CAGR % | 13.27 | 37.31 | 49.27 | 35.13 | 39.87 | |||||
Cash From Operations, 5 Yr. CAGR % | 14 | 1 | -5.73 | 19.61 | 17.68 | |||||
Capital Expenditures, 5 Yr. CAGR % | 74.88 | 48.01 | 3.18 | -11.99 | -5.46 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 13.55 | 22.91 | -1.25 | 4.78 | -0.9 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 13.31 | 22.82 | -1.67 | 4.49 | -1.35 |
- Stock Market
- Equities
- ONT Stock
- Financials Oxford Nanopore Technologies plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















